Rapport Therapeutics, Inc. (RAPP) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -818.8%, revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $13.62M |
| Revenue (TTM) | $0.0B |
| Net Margin | -818.8% |
| Return on Equity | -32.4% |
| Operating Margin (TTM) | -399.7% |
| Current Ratio | 15.72 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | 58.7% |
| FCF Growth (YoY) | 65.5% |
| Price / Book | 4.95 |
| Price / Sales | 75.30 |
| FCF Yield | -4.6% |
| Altman Z-Score | 44.75 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
RAPP overview · RAPP earnings · RAPP KPIs · RAPP documents · RAPP ownership · RAPP peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.